Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLPT ClearPoint Neuro	$11.68 -2.0%	$11.49	$9.46 ▼ $19.22	$326.91M	0.85	317,155 shs	511,212 shs
NPCE NeuroPace	$9.03 -3.1%	$10.09	$5.45 ▼ $18.98	$296.18M	1.89	276,276 shs	180,080 shs
OBIO Orchestra BioMed	$2.66	$3.00	$2.37 ▼ $7.04	$102.79M	0.62	297,127 shs	322,192 shs
TCMD Tactile Systems Technology	$12.38 -4.4%	$10.41	$8.61 ▼ $21.10	$275.95M	0.96	280,702 shs	206,655 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLPT ClearPoint Neuro	+13.09%	+10.47%	+0.59%	-7.74%	+20.28%
NPCE NeuroPace	+2.08%	+4.84%	-2.41%	-45.43%	+28.02%
OBIO Orchestra BioMed	-2.21%	+0.76%	-12.21%	-7.96%	-55.37%
TCMD Tactile Systems Technology	+3.02%	+7.74%	+28.98%	+34.20%	+1.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLPT ClearPoint Neuro	1.6841 of 5 stars	3.5	1.0	1.7	0.8	0.6
NPCE NeuroPace	3.3297 of 5 stars	3.5	3.0	2.1	4.2	0.6
OBIO Orchestra BioMed	3.3775 of 5 stars	3.6	5.0	3.0	2.5	0.0
TCMD Tactile Systems Technology	2.6152 of 5 stars	1.2	3.0	3.2	2.5	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLPT ClearPoint Neuro	3.00	Buy	$19.67	68.38% Upside
NPCE NeuroPace	3.00	Buy	$16.60	83.83% Upside
OBIO Orchestra BioMed	3.20	Buy	$14.00	426.32% Upside
TCMD Tactile Systems Technology	2.40	Hold	$13.50	9.05% Upside

Current Analyst Ratings Breakdown

Latest OBIO, CLPT, NPCE, and TCMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	NPCE NeuroPace	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$17.00 ➝ $15.00
8/13/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/7/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/5/2025	TCMD Tactile Systems Technology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/5/2025	TCMD Tactile Systems Technology	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00 ➝ $13.00
8/1/2025	CLPT ClearPoint Neuro	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $9.00
5/28/2025	NPCE NeuroPace	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
5/14/2025	NPCE NeuroPace	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $16.00
5/14/2025	NPCE NeuroPace	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$17.00 ➝ $17.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLPT ClearPoint Neuro	$33.59M	9.73	N/A	N/A	$0.92 per share	12.70
NPCE NeuroPace	$84.31M	3.51	N/A	N/A	$0.27 per share	33.44
OBIO Orchestra BioMed	$2.89M	35.62	N/A	N/A	$0.87 per share	3.06
TCMD Tactile Systems Technology	$292.98M	0.94	$1.07 per share	11.61	$8.74 per share	1.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLPT ClearPoint Neuro	-$18.91M	-$0.81	N/A	N/A	N/A	-66.15%	-89.64%	-60.91%	N/A
NPCE NeuroPace	-$27.14M	-$0.84	N/A	N/A	N/A	-29.29%	-184.84%	-25.84%	N/A
OBIO Orchestra BioMed	-$61.02M	-$1.83	N/A	N/A	N/A	-2,367.49%	-217.73%	-99.31%	N/A
TCMD Tactile Systems Technology	$16.96M	$0.62	19.97	14.74	N/A	5.06%	7.72%	5.59%	N/A

Latest OBIO, CLPT, NPCE, and TCMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CLPT ClearPoint Neuro	-$0.20	-$0.21	-$0.01	-$0.21	$9.20 million	$9.22 million
8/12/2025	Q2 2025	NPCE NeuroPace	-$0.24	-$0.26	-$0.02	-$0.26	$23.08 million	$23.52 million
8/12/2025	Q2 2025	OBIO Orchestra BioMed	-$0.51	-$0.50	+$0.01	-$0.50	$0.78 million	$0.84 million
8/4/2025	Q2 2025	TCMD Tactile Systems Technology	$0.09	$0.14	+$0.05	$0.14	$73.93 million	$78.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLPT ClearPoint Neuro	N/A	N/A	N/A	N/A	N/A
NPCE NeuroPace	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A
TCMD Tactile Systems Technology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLPT ClearPoint Neuro	N/A	3.53	2.57
NPCE NeuroPace	2.46	6.63	5.70
OBIO Orchestra BioMed	0.85	3.35	3.34
TCMD Tactile Systems Technology	0.11	3.79	3.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLPT ClearPoint Neuro	30.08%
NPCE NeuroPace	78.83%
OBIO Orchestra BioMed	53.20%
TCMD Tactile Systems Technology	83.43%

Insider Ownership

Company	Insider Ownership
CLPT ClearPoint Neuro	6.97%
NPCE NeuroPace	20.50%
OBIO Orchestra BioMed	8.10%
TCMD Tactile Systems Technology	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLPT ClearPoint Neuro	110	27.99 million	26.04 million	Optionable
NPCE NeuroPace	170	32.80 million	26.08 million	Optionable
OBIO Orchestra BioMed	4	38.64 million	35.51 million	Not Optionable
TCMD Tactile Systems Technology	1,037	22.29 million	21.74 million	Optionable

OBIO, CLPT, NPCE, and TCMD Headlines

Recent News About These Companies

Koss Olinger Consulting LLC Takes Position in Tactile Systems Technology, Inc. (NASDAQ:TCMD)

August 11 at 4:53 AM | marketbeat.com

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Given Average Rating of "Hold" by Analysts

August 11 at 3:45 AM | americanbankingnews.com

Blair William & Co. IL Reduces Position in Tactile Systems Technology, Inc. (NASDAQ:TCMD)

August 10, 2025 | marketbeat.com

Tactile Systems Technology (NASDAQ:TCMD) Upgraded by Wall Street Zen to Buy Rating

August 10, 2025 | marketbeat.com

What is B. Riley's Estimate for TCMD Q1 Earnings?

August 8, 2025 | marketbeat.com

Q3 Earnings Forecast for TCMD Issued By William Blair

August 8, 2025 | marketbeat.com

Equities Analysts Issue Forecasts for TCMD Q1 Earnings

August 8, 2025 | americanbankingnews.com

What is B. Riley's Forecast for TCMD Q3 Earnings?

August 8, 2025 | americanbankingnews.com

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Recommendation of "Hold" from Analysts

August 7, 2025 | marketbeat.com

William Blair Upgrades Tactile Systems Technology (NASDAQ:TCMD) to Strong-Buy

August 7, 2025 | marketbeat.com

B. Riley Analysts Reduce Earnings Estimates for TCMD

August 7, 2025 | marketbeat.com

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q2 2025 Earnings Call Transcript

August 7, 2025 | msn.com

Tactile Systems Technology (NASDAQ:TCMD) Earns "Neutral" Rating from B. Riley

August 7, 2025 | americanbankingnews.com

B. Riley Issues Positive Forecast for Tactile Systems Technology (NASDAQ:TCMD) Stock Price

August 6, 2025 | marketbeat.com

Is Tactile Systems Technology (TCMD) Stock Undervalued Right Now?

August 6, 2025 | zacks.com

Tactile Systems Technology (TCMD) Just Overtook the 20-Day Moving Average

August 6, 2025 | zacks.com

Tactile Systems Technology (TCMD) Recently Broke Out Above the 50-Day Moving Average

August 6, 2025 | zacks.com

Tactile Systems outlines 2025 revenue guidance of $310M-$315M while strengthening airway clearance growth

August 6, 2025 | msn.com

Tactile Systems Technology (NASDAQ:TCMD) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

August 5, 2025 | marketbeat.com

Tactile Systems Technology, Inc. (TCMD) Q2 2025 Earnings Call Transcript

August 4, 2025 | seekingalpha.com

Tactile Systems Technology (TCMD) Surpasses Q2 Earnings and Revenue Estimates

August 4, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO, CLPT, NPCE, and TCMD Company Descriptions

ClearPoint Neuro NASDAQ:CLPT

$11.68 -0.24 (-2.01%)

Closing price 04:00 PM Eastern

Extended Trading

$11.56 -0.12 (-0.98%)

As of 05:19 PM Eastern

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

NeuroPace NASDAQ:NPCE

$9.03 -0.29 (-3.11%)

Closing price 04:00 PM Eastern

Extended Trading

$9.02 -0.01 (-0.11%)

As of 04:44 PM Eastern

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Orchestra BioMed NASDAQ:OBIO

$2.66 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.70 +0.03 (+1.32%)

As of 05:29 PM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Tactile Systems Technology NASDAQ:TCMD

$12.38 -0.57 (-4.40%)

Closing price 04:00 PM Eastern

Extended Trading

$12.40 +0.02 (+0.19%)

As of 05:40 PM Eastern

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time